Orforglipron, a novel oral medication, has shown promise in treating type 2 diabetes and inadequate glycemic control. Clinical trials, including phase 3 trials, have demonstrated its effectiveness, with some studies comparing it favorably to other treatments such as semaglutide. The medication, also known as Foundayo, has been approved by the FDA, although its specific approvals and potential side effects are still being reported.